May 2025 Patent Highlights: Eisbach’s ALC1 inhibitor

ALC1 (amplified in liver cancer 1; also known as CHD1L, chromodomain helicase DNA-binding protein 1-like) is a chromatin remodeling enzyme that plays a critical role in modulating DNA damage and repair processes. Elevated expression of ALC1 has been observed in breast and ovarian cancers characterized by homologous recombination deficiencies (HRD-positive). Notably, the absence of ALC1 significantly enhances the efficacy of PARP inhibitors as well as a broad spectrum of standard-of-care chemotherapeutic agents. ALC1 inhibitors are anticipated to induce synthetic lethality in HR-deficient tumors, potentiate the effects of PARP inhibitors in patients who develop resistance to PARPi, and facilitate highly effective combination therapies. 

Eisbach Bio GmbH has disclosed two patent applications primarily focused on the use of ALC1 inhibitors in cancer treatment: WO2025088087A1 and WO2025088175A1. Eisbach is a privately held company founded in 2019 by academic and drug discovery pioneers, with its headquarters located in Munich, Germany. The company is dedicated to discovering and developing transformative anti-cancer drugs by leveraging the potential of synthetic lethality through unique molecular vulnerabilities present in validated cancer targets. Its clinical operations are based in Houston, Texas. In November 2024, Eisbach was awarded the Texas Therapeutics Company Award by the Cancer Prevention and Research Institute of Texas (CPRIT). This significant $4.75 million grant will support the clinical development of Eisbach’s first-in-class, allosteric small molecule inhibitor, EIS-12656, which targets ALC1.

 ALCli-1

WO2025088087

Eisbach

WO2025088175

Eisbach

In the WO2025088087A1, Eisbach notes that although ALCli-1 may not be the most effective inhibitor of ALC1 nucleosome sliding, its properties make it a promising candidate for cancer treatment.These compounds, disclosed in WO2025088175, show limited molecular structure innovation compared to Eisbach's previously published patents and primarily highlight the potential of ALC1 inhibitors in combination therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!